Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Clinical Trial to Demonstrate Efficacy / Safety of Liposomal Cyclosporine a + Standard of Care (SoC) Vs SoC Alone in Treating Chronic Lung Allograft Dysfunction / Bronchiolitis Obliterans in Patients Post Single Lung Transplant

Next Previous
Search
Trial Profile

A Phase III Clinical Trial to Demonstrate Efficacy / Safety of Liposomal Cyclosporine a + Standard of Care (SoC) Vs SoC Alone in Treating Chronic Lung Allograft Dysfunction / Bronchiolitis Obliterans in Patients Post Single Lung Transplant

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciclosporin (Primary)
  • Indications Bronchiolitis obliterans
  • Focus Registrational; Therapeutic Use
  • Acronyms BOSTON-1
  • Sponsors Breath Therapeutics; Zambon Company SpA

    • Most Recent Events

    • 27 Jan 2025 Status changed from active, no longer recruiting to completed.
    • 17 May 2024 This trial has been completed in France, according to the European Clinical Trials Database record.
    • 06 Oct 2023 Planned End Date changed from 1 Jun 2024 to 1 Nov 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top